The Most Up-to-Date Clinical Trial Technology

Increased clinical trial expenditures, as well as a higher rate of trial failures and a rise in patient-centric trials, have fueled a surge in demand for technology adoption in clinical trials. The following are the primary difficulties that technology can address in the industry:

  • Incomplete patient registration: Despite a substantial amount of resources (about 30%) dedicated to patient recruiting, this is the case at roughly 48% of sites.
  • Procedural delays and length of time in the courtroom: Inefficient data management and a lack of evidence on patient outcomes cause long clinical trial schedules.
  • Low success rate of clinical trial: Trial failure is around 10 to 13 percent on average, with Phase 2 to Phase 3 being the most challenging transition for most drug candidates. Figure 1 shows the various technologies that are being used throughout the drug development process.

Technology Market of Global R&D

Various organizational and clinical trial implications are driving the adoption of technologies in the R&D market at a rate of around 22 to 23 percent. Technology adoption has proven to be time and cost-efficient for sponsors.

In clinical trials, technology is applied primarily to capture real-world data (or real-world evidence, RWE), improve patient adherence, and speed up enrollment of patients.

Today, the North American R&D technology market makes up 40 percent, but it is expected to grow substantially in the next five years.

Next largest in technology adoption, Europe has a robust infrastructure and widespread use of EHRs and mobile devices.

The Asia-Pacific region’s contribution, although relatively low, is forecast to rise as clinical trials increase there, especially in China, India, Japan, and the Philippines.

Adoption of technology is driven by trends

Smaller trials: Disruptive technologies such as wearables, mobile health, and RWE have made it easier to conduct smaller trials. Every aspect of the trial, including enrollment and drug administration, is done through the mobile phone given to trial participants.

In a recent Phase 2 study, Science 37 conducted siteless Phase 2 trials with AOBiome for acne, reducing patient enrollment time by half while also creating a diverse pool of participants and informing clinical endpoints.

In order to remain competitive: pharma companies are investing more in AI and Big Data analytics, as these tools have transformative power over the R&D process and can save companies significant sums of money. Besides business transformation and agility, competition in the market is a key driver of huge investments.

Targeting adherence with ingestible sensors: A rising interest in technology by pharma companies has been driven by increased impact on adherence.

Wearables and ingestible sensors like Abilify MyCite and the new use of AI-driven chatbots to monitor patient outcomes all prove that this trend is flourishing in pharma research. For example: To prevent strokes, Janssen is collaborating with Scripps Translational Science Institute, Aetna, and iRhythm Technologies to detect aFIB remotely using mHealth screening.

Collaborations in the market for virtual clinical trials: are increasingly used by pharma companies.

Clinical trials run in the United States account for only 3 percent of all trials, but this greatly increases participation. For example, Boehringer Ingelheim and Science 37, for example, are working together to perform remote clinical studies using the NORA platform.

Technologies that are on the rise

The technologies listed below are projected to change patient recruitment, patient engagement, trial data management, and endpoint data gathering for quick post-market approval.

Artificial Intelligence In Growth Stage

Given the advancement of supplier maturity and its ability to optimise clinical trial procedures, investment in AI technology for pharma R&D is rapidly expanding. Pharma can fully harness the technology’s benefits through strategic partnerships and co-investment transactions thanks to the presence of a large number of specialist players.

Given its strong adoption in Phase 1 and ramifications for other areas of pharma, AI penetration in R&D is now at 25% and is likely to expand. The AI supply business is highly fragmented, with a number of specialist suppliers, and it has just recently progressed from the nascent to the growth stage of the technological adoption curve.

Big Data Analytics In Growth Stage

The most significant advantage of implementing Big Data technology is that it allows for decision-making across the value chain, from discovery research to real-world applications.

Real-world data from EHRs/EMRs, lab data, genetics data, and trial data, combined with machine learning and artificial intelligence, will be helpful in designing clinical trials that are successful.

Increased M&As of specialty technology suppliers with Big Data organisations and CROs in the clinical research industry are occurring in the supply market, with the goal of forming strategic relationships with pharma by delivering end-to-end services.

Blockchain In developing Stage

Although blockchain integration into clinical research studies is still in its early stages, pharma’s continued collaboration with blockchain suppliers will enable its application across various aspects of the clinical trial value chain, streamlining the process and providing time, cost, and security benefits.

The use of blockchain in research and development is at 15%, with supply maturity still in its infancy. The market appears to be dominated by startups with highly specialised knowledge.

Clinical Trial Payments In Growth Stage

In the coming years, clinical trial technology investment will primarily be focused on Big Data and blockchain. Suppliers have been able to quickly grow up and develop because of widespread usage of clinical trial management systems (CTMSs) and mobile payments.

Supplier innovation will be largely determined by their ability to integrate with other technologies and their ease of use. The present acceptance rate is at 80%, and as a result of the growing adoption, the supply market is approaching maturity.

Patient Engagement Solutions In Growth Stage

To promote patient involvement, there is an increasing investment in digital technologies to build patient-centric products. Patient engagement solutions continue to emphasise mobile health, electronic health records, and patient-generated data.

There is an increased adoption of customer-centric well-being products, which has resulted in a 60 percent adoption rate for these solutions. As suppliers innovate to develop better and more efficient ways to engage patients, the supply market is in the growth stage.

Here is Conclusion:

Wearables, mHealth, and RWE, among other disruptive technologies, are opening the way for small, controlled clinical trials. Everything is done through the phone provided to trial participants, from patient enrollment to drug administration to follow-ups.

As a result of the powerful and cost-saving effects of AI and Big Data analytics, pharmaceutical companies have invested more in these technologies in recent years. Business transformation and agility, as well as fear of competition in the market, are strong factors driving R&D investments.

Hence, pharmaceutical companies need to identify external innovation in each of these categories through supplier benchmarking and engage in early engagement through co-development to remain competitive.